Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Sun, R.J
GLP-1 receptor agonists have well-characterized safety profiles based on extensive use in diabetes and obesity management, but specific considerations apply when considering their use in patients with substance use disorders
Researchers continue to investigate this peptide combination in studies involving peptide signalling, receptor pharmacology, molecular biology, and endocrine-related research under controlled laboratory conditions
Metabolism , 92
Obesity and GLP-1
US$ 24.15
US$ 20.21
US$ 26.81
US$ 20.63
US$ 28.80
